[{"id":"046bd970-a819-491c-b309-6d96f8ea30b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03941626","created_at":"2021-01-19T18:01:10.172Z","updated_at":"2024-07-02T16:36:35.027Z","phase":"Phase 1/2","brief_title":"Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies","source_id_and_acronym":"NCT03941626","lead_sponsor":"Shenzhen BinDeBio Ltd.","biomarkers":" HLA-A • MSLN • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • MSLN positive • HLA-A positive","tags":["HLA-A • MSLN • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • MSLN positive • HLA-A positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • multi-target gene-modified CAR-T/TCR-T cell immunotherapy"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 05/01/2021","primary_completion_date":" 05/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2021-02-04"},{"id":"031439da-5f9c-460c-8c05-2a1c5a400206","acronym":"","url":"https://clinicaltrials.gov/study/NCT03638206","created_at":"2021-01-18T17:51:53.397Z","updated_at":"2024-07-02T16:36:52.614Z","phase":"Phase 1/2","brief_title":"Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies","source_id_and_acronym":"NCT03638206","lead_sponsor":"Shenzhen BinDeBio Ltd.","biomarkers":" MET • CD19 • HLA-A • MSLN • CD22 • CD33 • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • CD19 expression • HLA-A positive","tags":["MET • CD19 • HLA-A • MSLN • CD22 • CD33 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • CD19 expression • HLA-A positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CAR-T cell immunotherapy • multi-target gene-modified CAR-T/TCR-T cell immunotherapy"],"overall_status":"Recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2019-12-11"},{"id":"ad059291-02b5-4149-a5a6-12c4efa5c771","acronym":"","url":"https://clinicaltrials.gov/study/NCT03672305","created_at":"2021-01-18T18:00:49.358Z","updated_at":"2024-07-02T16:37:06.818Z","phase":"Phase 1","brief_title":"Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC","source_id_and_acronym":"NCT03672305","lead_sponsor":"The Second Hospital of Nanjing Medical University","biomarkers":" PD-L1 • MET","pipe":" | ","alterations":" MET amplification • MET positive","tags":["PD-L1 • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET positive"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 10/01/2018","start_date":" 10/01/2018","primary_txt":" Primary completion: 10/30/2019","primary_completion_date":" 10/30/2019","study_txt":" Completion: 10/30/2019","study_completion_date":" 10/30/2019","last_update_posted":"2018-09-18"}]